Bcr-Abl kinase inhibitors (SGX/Novartis)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBcr-Abl kinase inhibitors (SGX/Novartis)
Drug Alias NameBcr-Abl kinase inhibitors (Structural Genomix/Novartis)SGX-66830SGX-67686SGX-70508SGX-70430 +[6] 
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSgx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgSgx Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A